GlassScriptPhysician profile
Palak Parekh
NPI 1407512247
$2,074.17
in general payments reported to CMS, 2019-2025
30 companies · $1,754 in 2025
The $1,754 reported for 2025 was more than what 94% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $87.51 · 2023: $101 · 2024: $132 · 2025: $1,754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,637 · Education: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,636.68 |
| Education | $349.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $824.48 | 2025 | Trodelvy |
| Novo Nordisk INC | $139.75 | 2024-2025 | Ozempic, Rybelsus |
| Insmed, INC. | $100.80 | 2023 | Arikayce |
| Sobi, INC | $96.31 | 2025 | |
| Incyte Corporation | $90.76 | 2025 | Jakafi |
| Seagen INC. | $80.00 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $74.39 | 2025 | |
| Urovant Sciences INC | $69.30 | 2022 | |
| La Jolla Pharmaceutical Company | $63.29 | 2024 | Giapreza |
| E.R. Squibb & Sons, L.L.C. | $54.40 | 2025 | Opdivo |
| Merck Sharp & Dohme LLC | $51.53 | 2024-2025 | Verquvo, Lynparza, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $49.99 | 2025 | Enhertu |
| Genzyme Corporation | $35.44 | 2025 | |
| Daiichi Sankyo INC. | $34.95 | 2025 | Vanflyta, Injectafer |
| Novartis Pharmaceuticals Corporation | $24.92 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $22.73 | 2025 | Orserdu |
| Janssen Pharmaceuticals, INC | $21.17 | 2025 | Tecvayli |
| Glaxosmithkline, LLC. | $20.62 | 2025 | Zejula, Jemperli |
| Eisai INC. | $19.91 | 2025 | |
| Pfizer INC. | $19.39 | 2025 | |
| Genentech USA, INC. | $19.25 | 2025 | Polivy |
| Astellas Pharma US INC | $19.19 | 2025 | Vyloy |
| Beone Medicines USA, INC. | $19.15 | 2025 | Tevimbra |
| Janssen Biotech, INC. | $18.75 | 2025 | Tecvayli |
| Pharmaessentia USA Corporation | $18.75 | 2025 | Besremi |
| Medtronic, INC. | $18.21 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $17.99 | 2025 | Libtayo |
| Geron Corporation | $16.68 | 2025 | Rytelo |
| Edwards Lifesciences Corporation | $16.57 | 2024 | |
| Abbvie INC. | $15.50 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Palak Parekh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.